% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Bochtler:119669,
      author       = {T. Bochtler$^*$ and U. Hegenbart and C. Kunz$^*$ and A.
                      Benner$^*$ and A. Seckinger and S. Dietrich and M. Granzow
                      and K. Neben and H. Goldschmidt$^*$ and A. D. Ho and D. Hose
                      and A. Jauch and S. O. Schönland},
      title        = {{G}ain of chromosome 1q21 is an independent adverse
                      prognostic factor in light chain amyloidosis patients
                      treated with melphalan/dexamethasone.},
      journal      = {Amyloid},
      volume       = {21},
      number       = {1},
      issn         = {1744-2818},
      address      = {Abingdon},
      publisher    = {Taylor $\&$ Francis Group},
      reportid     = {DKFZ-2017-00300},
      pages        = {9 - 17},
      year         = {2014},
      abstract     = {Chromosomal aberrations of plasma cells are well
                      established pathogenetic and prognostic factors in multiple
                      myeloma, but their prognostic implication in systemic light
                      chain (AL) amyloidosis is unclear. Therefore, the aim of
                      this study was to identify prognostic cytogenetic risk
                      factors by interphase FISH in a series of 103 consecutive AL
                      amyloidosis patients treated uniformly with
                      melphalan/dexamethasone as first-line therapy. Detection of
                      gain of 1q21 was predictive for a poor overall survival (OS)
                      (median 12.5 versus 38.2 months, p = 0.002).
                      Hematologic event free survival (hem EFS) for gain of 1q21
                      was 5.0 versus 8.5 months in median (p = 0.08) and
                      haematologic remission rates (≥VGPR) after three cycles
                      were $5\%$ versus $25\%$ (p = 0.06). Most important, in
                      multivariate concordance analyses the adverse prognosis
                      carried by gain of 1q21 was retained as an independent
                      prognostic factor (OS: p = 0.003, average hazard ratio
                      (AHR) = 3.64, hemEFS: p = 0.008, AHR = 2.35),
                      along with the well established Mayo cardiac staging.
                      Patients with t(11;14) had a longer median OS with
                      38.2 months versus 17.5 months, though no statistical
                      significance was reached. Deletion 13q14 and hyperdiploidy
                      turned out to be prognostically neutral. In conclusion, we
                      have identified gain of 1q21 as an independent adverse
                      prognostic factor in AL amyloidosis patients treated with
                      standard chemotherapy.},
      keywords     = {Immunoglobulin Light Chains (NLM Chemicals) / Dexamethasone
                      (NLM Chemicals) / Melphalan (NLM Chemicals)},
      cin          = {G330 / C060},
      ddc          = {610},
      cid          = {I:(DE-He78)G330-20160331 / I:(DE-He78)C060-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:24455967},
      doi          = {10.3109/13506129.2013.854766},
      url          = {https://inrepo02.dkfz.de/record/119669},
}